azacitidine mylan
mylan ireland limited - azacitidinnel - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - daganatellenes szerek - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.
azacitidine zentiva 25 mg/ml por szuszpenziós injekcióhoz
zentiva, k.s. (csehország) - azacitidinnel -
azacitidine oncoeurope 25 mg/ml por szuszpenziós injekcióhoz
pharmacenter europe kft. - azacitidinnel -
pemetrexed zentiva 10 mg/ml oldatos infúzió
zentiva, k.s. (csehország) - pemetrexed -
imatinib pharmacenter 100 mg filmtabletta
pharmacenter europe kft. - imatinib -
imatinib pharmacenter 400 mg filmtabletta
pharmacenter europe kft. - imatinib -
capecitabine pharmacenter 150 mg filmtabletta
pharmacenter europe kft. - kapecitabin -
capecitabine pharmacenter 500 mg filmtabletta
pharmacenter europe kft. - kapecitabin -